Weill Cornell GI Oncology Program

06/03/2026

Dr. Despina Siolas spoke to PBS NewsHour about promising presented at the plenary session evaluating a new pill-based therapy for this difficult to treat disease:

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

06/02/2026

Third-year fellow Dr. Jonathan Lee shares additional details on with Dr. Manish Shah that was shared at . Learn more about the Weill Cornell Medicine experience with liver transplantation for metastatic in the liver: https://bit.ly/4nQd1eW

06/01/2026

Dr. Manish Shah explains insights from Weill Cornell Medicine research shared at on liver transplantation for metastatic : https://bit.ly/4wSG5Xh

05/28/2026

Dr. Manish Shahco-chaired an expert panel tasked with revising the American Society of Clinical Oncology guideline for and targeted therapy for patients with advanced . Learn more about the updated guideline recently published in the Journal of Clinical Oncology (JCO) :

Biomarker testing still informs therapy as new targeted therapies plus chemotherapy improve outcomes

05/26/2026

Dr. Jonathan Lee provided commentary on key being shared at including emerging treatments for , and :

Ahead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.

05/23/2026

The U.S. Food and Drug Administration granted priority review for the combination of Tevimbra / Ziihera and for a subset of and patients. Dr. Manish Shah commented on the evaluating this treatment regimen:

The FDA has set a Prescription Drug User Fee Act (PDUFA) date of Aug. 25, 2026, for the combination of Tevimbra/Ziihera as a first-line treatment for advanced cancers of the stomach, gastroesophageal junction, and esophagus.

04/17/2026

The liver plays a very important role in cancer care due to the body’s anatomy and its role in processing nutrients and medications. Treatments for and metastatic disease are rapidly evolving through precision surgery, targeted therapies and new “no-cut” technologies that can destroy tumors without removing them. These innovations are helping doctors target tumors more effectively, reducing recovery time, and increasing treatment access for more patients than ever before, including patients with liver metastases. Learn more:

Liver cancer care is evolving quickly with new tools and technologies that are helping to expand what treatment is possible for patients with both primary liver tumors and other forms of cancer that have spread to the liver, also known as metastatic disease.

04/14/2026

Mismatch repair-deficient is a form of caused by mutations in some of the genes involved in correcting mistakes made when DNA is copied in a cell. It’s important to understand how this genetic abnormality is actually opening the door to new and more effective treatment options, like immunotherapy, for this subtype. An in-depth look at the why behind these advances and what patients and loved ones should know:

Mismatch repair-deficient (dMMR) colon cancer, also known as microsatellite instability-high (MSI-H), is a biologically distinct form of colorectal cancer caused by mutations in some of the genes that are involved in correcting mistakes made when DNA is copied in a cell. This type of colon cancer is...

04/08/2026

Innovative liver-directed therapies continue to expand treatment options for and liver metastases. Transplantation, surgery, histotripsy and ablation are giving patients more options than ever before. In this episode of CancerCast, Dr. Manish Shah is joined by Dr. Juan Rocca, Surgical Director of the Weill Cornell Liver Cancer Program, to break down the liver’s role in cancer care and the latest treatment updates. Listen: https://bit.ly/4jDZGo2

04/02/2026

In another Targeted Oncology interview, Dr. Rutika Mehta talks about gaps that should be addressed before circulating tumor DNA (ctDNA) testing is more widely integrated into standard of care for patients:

New study signals ctDNA MRD clearance and 90% drops predict better gastroesophageal cancer outcomes, fueling calls for prospective trials.